Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic rhinosinusitis with nasal polyps, teeing up a potential n
Ionis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug to treat advanced age-related macular degeneration (AMD), a leading cause of blindness.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
